Concentration-dependent inhibitory effect of irbesartan on renal uric acid transporters.
Hyperuricemia is currently recognized as a risk factor for cardiovascular diseases. It has been reported that the angiotensin II-receptor blocker (ARB) losartan decreases serum uric acid level. In this study, the effects of another ARB, irbesartan, on [(14)C]uric acid-transport activity of renal uric acid reabsorptive transporters URAT1 and URATv1 were examined with Xenopus oocytes expressing each transporter. The results showed that irbesartan (100-500 µM) inhibited the uptake of uric acid via both transporters. The inhibitory effects of irbesartan exceeded those of losartan and other ARBs, and the results suggest that irbesartan can reduce serum uric acid level.
Nakamura
Makiko
M
Department of Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Anzai
Naohiko
N
Jutabha
Promsuk
P
Sato
Hiroyuki
H
Sakurai
Hiroyuki
H
Ichida
Kimiyoshi
K
D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D000077405:Irbesartan; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D027361:Organic Anion Transporters / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D027701:Organic Cation Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013777:Tetrazoles / Q000494:pharmacology*; D014527:Uric Acid / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014981:Xenopus
D001713:Biphenyl Compounds; D027361:Organic Anion Transporters; D027701:Organic Cation Transport Proteins; C491241:SLC22A12 protein, human; D013777:Tetrazoles; D014527:Uric Acid; D000077405:Irbesartan